This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

Summary

This is an open-label,early-stage exploratory clinical study to evaluate the safety and preliminary efficacy of GC012F CAR T cell injection in Multiple Sclerosis subjects.

Timeline

Start

2026-01-26

Primary completion

2026-03-25

Completion

2026-03-25

Outcome

Outcome not reported

Stopped (Enrollment): “Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study.”

Drugs

Indications